WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.

Disclosures for additional planners can be found here.

Faculty

William Herrington, MD, FRCP

Associate Professor
MRC Population Health Research Unit
University of Oxford
Oxford, United Kingdom

Disclosures

William Herrington, MD, FRCP, has the following relevant financial relationships:
Research funding from: Boehringer Ingelheim; Eli Lilly and Company

Natalie Staplin, PhD

Associate Professor
Senior Statistician
MRC Population Health Research Unit
University of Oxford
Oxford, United Kingdom

Disclosures

Natalie Staplin, PhD, has the following relevant financial relationships:
Research funding from: Boehringer Ingelheim; Eli Lilly and Company; Novo Nordisk

David Cherney, MD, PhD

Professor of Medicine
University of Toronto
Clinician Scientist
Division of Nephrology, UHN
Toronto, Canada

Disclosures

David Cherney, MD, PhD, has the following relevant financial relationships:
Consultant or advisor for: AbbVie; AstraZeneca; Bayer; Boehringer Ingelheim-Lilly; Bristol Myers Squibb; CSL Behring; Gilead Sciences; Janssen; Lexicon Pharmaceuticals; Maze Therapeutics; Merck; Mitsubishi-Tanabe; Novartis; Novo Nordisk; Otsuka Pharmaceutical; Prometic Life Sciences Inc. (now, Limial BioSciences); Youngene Therapeutics
Research funding from: AstraZeneca; Boehringer Ingelheim-Lilly; CSL Behring; Janssen; Merck; Novo Nordisk; Sanofi

Susanne Nicholas, MD, MPH, PhD

Professor of Medicine
David Geffen School of Medicine
University of California
Los Angeles, California, United States

Disclosures

Susanne Nicholas, MD, MPH, PhD, has the following relevant financial relationships:
Consultant or advisor for: AstraZeneca; Bayer; Boehringer-Ingelheim-Lilly; Janssen
Speaker or member of speakers bureau for: AstraZeneca; Boehringer Ingelheim-Lilly
Research funding from: Bayer; Goldfinch Bio; Travere Therapeutics

Christoph Wanner, MD

Professor of Medicine
University of Würzburg
Würzburg, Germany

Disclosures

Christoph Wanner, MD, has the following relevant financial relationships:
Consultant or advisor for: AstraZeneca; Bayer; Boehringer Ingelheim; GlaxoSmithKline
Speaker or member of speakers bureau for: Bayer; Boehringer Ingelheim; Eli Lilly and Company; Fresenius Medical Care; GlaxoSmithKline

Editor

Rita Moreira Da Silva, PhD, MA, PharmD

Medical Education Director, WebMD Global, LLC

Disclosures

Rita Moreira Da Silva, PhD, MA, PharmD, has no relevant financial relationships.

Compliance Reviewer

Lisa Simani, APRN, MS, ACNP

Associate Director, Accreditation and Compliance

Disclosures

Lisa Simani, APRN, MS, ACNP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

From Medscape Education

EMPA-Kidney in Context: Expanding Our Understanding of Sodium-Glucose Cotransporter 2 Inhibition in Chronic Kidney Disease Management

Authors: William Herrington, MD, FRCP; Natalie Staplin, PhD; David Cherney, MD, PhD; Susanne Nicholas, MD, MPH, PhD; Christoph Wanner, MDFaculty and Disclosures

processing....

Posted: 28/12/2022

This educational activity is intended for an international audience of non-US primary care physicians, diabetologists/endocrinologists, and nephrologists (excluding UK & Ireland).

The goal of this activity is for learners to be better able to detect chronic kidney disease (CKD) early and integrate reno-protective therapies, such as sodium-glucose cotransporter 2 (SGLT2) inhibitors, into CKD management.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Close association between metabolic, renal, and cardiovascular diseases
- Latest results of CKD outcome trials with reno-protective drugs
Have greater competence related to
- The practical use of SGLT2 inhibitors with proven kidney benefit in a broad range of patients with CKD

Contents of This Activity

All sections of this activity are required for credit.

EMPA-KIDNEY in Context: Latest Findings Presented at ASN Kidney Week 2022

Did you know how that EMPA-KIDNEY evaluated patients with and without diabetes across a large range of eGFRs as low as 20 mL/min/1.73 m²?
William Herrington, MD, FRCP

EMPA-KIDNEY in Context: How Do Data Compare With Other Major Cardio-Renal Outcome Trials with SGLT2 Inhibitors?

Did you know that a meta-analysis conducted to assess effect modification by primary kidney diagnosis in CKD trials using SGLT2 inhibitors showed that the relative benefits were obtained irrespective of diabetes status?
William Herrington, MD, FRCP; Natalie Staplin, PhD

EMPA-KIDNEY Study Design: How Does It Differ From Other Major Cardio-Renal Outcome Trials With SGLT2 Inhibitors

What are the similarities and differences between the study design of EMPA-KIDNEY compared with other major cardiorenal outcome trials with SGLT2 inhibitors?
David Cherney, MD, PhD

EMPA-KIDNEY: Implications for the Practical Management of Patients With CKD

Are you aware of the therapeutic implications of EMPA-KIDNEY for the practical management of patients with CKD?
Susanne Nicholas, MD, MPH, PhD

EMPA-KIDNEY: How Do We Define Patients With CKD Who Would Benefit From SGLT2 Inhibitor Treatment?

Do you know who among your patients with CKD will best benefit from treatment with an SGLT2 inhibitor?
Christoph Wanner, MD; David Cherney, MD, PhD

Educational Impact Challenge

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Page 1 of 10

Download Slides

Activity Transcript

PDF Downloads

Transcript Downloads

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred.

The material presented here does not necessarily reflect the views of WebMD, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been authorized by the European Medicines Agency for use in Europe, off-label uses of authorized products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Faculty

William Herrington, MD, FRCP

Natalie Staplin, PhD

David Cherney, MD, PhD

Susanne Nicholas, MD, MPH, PhD

Christoph Wanner, MD